Global Pharmacogenomics Market

Pharmacogenomics Comprehensive Study by Technology (Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Others), End User (Hospitals & Clinics, Research Institutions, Academic Institutes, Others), Application Names (Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, Others) Players and Region - Global Market Outlook to 2026

Pharmacogenomics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Pharmacogenomics Market Scope?
Pharmacogenomics is defined as the tailoring of medical treatment in order to the specific characteristics of each patient. It is also known as personalized medicine. It is also widely used for cancer treatment in order to improve the survival of patients. It also examines how the genetic makeup of an individual affects human responses to drugs. On 2017, as per an article published by the Organization for Economic Co-operation and Development (France), biotech R&D in the business enterprise sector was 11.3%, and 9.4% for the United States. Growth in the prevalence of chronic diseases for instance, cancer, tuberculosis, HIV, and others are some of the major drivers which are propelling the growth of the market. The global Pharmacogenomics market is anticipated to grow at a CAGR of 6.2 % during the forecast period.

The Pharmacogenomics market study is being classified and major geographies with country level break-up.

The market is fragmented with numerous players focusing on technique and quality of the product due to which the global pharmacogenomics market can witness an upsurge in the forecast period Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Pharmacogenomics market throughout the predicted period.

Abbott Laboratories, Inc. (United States), Affymetrix, Inc. (United States), AstraZeneca plc (United Kingdom), Assurex Health (United States), Bayer AG (Germany), GeneDX (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc., (United States), Myriad Genetics, Inc., (United States) and Merck & Co, (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are GE Healthcare (United States), GlaxoSmithKline, (United Kingdom), Johnson & Johnson (United States), Pfizer, Inc., (United States), Pathway Genomics (United States), Qiagen, Inc. (Germany), Teva Pharmaceutical Industries Ltd (Israel), Thermo Fisher Scientific (United States) and Transgenomic, Inc. (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Pharmacogenomics market by Type, Application and Region.

On the basis of geography, the market of Pharmacogenomics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On August 2017, the Albuquerque based company had received USD 1.5 Million from the states USD 40 Million catalyst fund. This will, in turn, propel the growth of the Pharmacogenomics market in futures, , On March 2016, the OneOme, LLC (United States) Company, which is a Pharmacogenomics company, announced today the hiring of Dr. Justin Odegaard, M.D., Ph.D., and Ross Higgins in order to manage and lead their Pharmacogenomics testing laboratory, and On November 2018, the American Society of Health-System Pharmacists (United States) Company had launched a professional certificate for Pharmacogenomics. This would help in enhancing the customer base of the company.
On March 2018, Food and Drug Administration (United States) reviewers evaluate the effect of genetic factors on drug safety, efficacy, or dose. In addition, it also provides advice to drug developers on how to use genomic biomarkers.

Influencing Market Trend
  • The Expansion and Advancement of the Pharmacogenomics

Market Drivers
  • Increase in Elderly Population Worldwide
  • Surge in adoption of Pharmacogenomics procedure by the Healthcare Professionals
  • Growing Awareness of the Patient Population towards Personalized Therapy

Opportunities
  • Rising Demand from Emerging Economics such as India, China and others
  • Surge in Disposable Income of the Global Population

Restraints
  • Dearth of skilled labor worldwide
  • Highly Trained Healthcare Professionals in Performing the Pharmacogenomics Diagnostics Test

Challenges
  • High Cost Associated with Tests
  • Lack of Funding For the Research & Development of Different Pharmacogenomics Pathways


Key Target Audience
Manufacturers of Pharmacogenomics, Suppliers of Pharmacogenomics, Wholesalers, Distributors and Retailers of Pharmacogenomics, Research and Development (R&D) Companies, Research Organization, Federal Agencies and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Technology
  • Sequencing
  • Polymerase Chain Reaction
  • Gel Electrophoresis
  • Mass Spectrometry
  • Microarray
  • Others

By End User
  • Hospitals & Clinics
  • Research Institutions
  • Academic Institutes
  • Others

By Application Names
  • Cardiovascular Diseases
  • Infectious Diseases
  • Oncology
  • Neurological Diseases
  • Psychiatry
  • Pain Management
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Elderly Population Worldwide
      • 3.2.2. Surge in adoption of Pharmacogenomics procedure by the Healthcare Professionals
      • 3.2.3. Growing Awareness of the Patient Population towards Personalized Therapy
    • 3.3. Market Challenges
      • 3.3.1. High Cost Associated with Tests
      • 3.3.2. Lack of Funding For the Research & Development of Different Pharmacogenomics Pathways
    • 3.4. Market Trends
      • 3.4.1. The Expansion and Advancement of the Pharmacogenomics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pharmacogenomics, by Technology, End User, Application Names and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pharmacogenomics (Value)
      • 5.2.1. Global Pharmacogenomics by: Technology (Value)
        • 5.2.1.1. Sequencing
        • 5.2.1.2. Polymerase Chain Reaction
        • 5.2.1.3. Gel Electrophoresis
        • 5.2.1.4. Mass Spectrometry
        • 5.2.1.5. Microarray
        • 5.2.1.6. Others
      • 5.2.2. Global Pharmacogenomics by: End User (Value)
        • 5.2.2.1. Hospitals & Clinics
        • 5.2.2.2. Research Institutions
        • 5.2.2.3. Academic Institutes
        • 5.2.2.4. Others
      • 5.2.3. Global Pharmacogenomics by: Application Names (Value)
        • 5.2.3.1. Cardiovascular Diseases
        • 5.2.3.2. Infectious Diseases
        • 5.2.3.3. Oncology
        • 5.2.3.4. Neurological Diseases
        • 5.2.3.5. Psychiatry
        • 5.2.3.6. Pain Management
        • 5.2.3.7. Others
      • 5.2.4. Global Pharmacogenomics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Pharmacogenomics (Price)
  • 6. Pharmacogenomics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Affymetrix, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Assurex Health (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GeneDX (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Illumina, Inc., (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Myriad Genetics, Inc., (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck & Co, (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pharmacogenomics Sale, by Technology, End User, Application Names and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pharmacogenomics (Value)
      • 7.2.1. Global Pharmacogenomics by: Technology (Value)
        • 7.2.1.1. Sequencing
        • 7.2.1.2. Polymerase Chain Reaction
        • 7.2.1.3. Gel Electrophoresis
        • 7.2.1.4. Mass Spectrometry
        • 7.2.1.5. Microarray
        • 7.2.1.6. Others
      • 7.2.2. Global Pharmacogenomics by: End User (Value)
        • 7.2.2.1. Hospitals & Clinics
        • 7.2.2.2. Research Institutions
        • 7.2.2.3. Academic Institutes
        • 7.2.2.4. Others
      • 7.2.3. Global Pharmacogenomics by: Application Names (Value)
        • 7.2.3.1. Cardiovascular Diseases
        • 7.2.3.2. Infectious Diseases
        • 7.2.3.3. Oncology
        • 7.2.3.4. Neurological Diseases
        • 7.2.3.5. Psychiatry
        • 7.2.3.6. Pain Management
        • 7.2.3.7. Others
      • 7.2.4. Global Pharmacogenomics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Pharmacogenomics (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pharmacogenomics: by Technology(USD Million)
  • Table 2. Pharmacogenomics Sequencing , by Region USD Million (2015-2020)
  • Table 3. Pharmacogenomics Polymerase Chain Reaction , by Region USD Million (2015-2020)
  • Table 4. Pharmacogenomics Gel Electrophoresis , by Region USD Million (2015-2020)
  • Table 5. Pharmacogenomics Mass Spectrometry , by Region USD Million (2015-2020)
  • Table 6. Pharmacogenomics Microarray , by Region USD Million (2015-2020)
  • Table 7. Pharmacogenomics Others , by Region USD Million (2015-2020)
  • Table 8. Pharmacogenomics: by End User(USD Million)
  • Table 9. Pharmacogenomics Hospitals & Clinics , by Region USD Million (2015-2020)
  • Table 10. Pharmacogenomics Research Institutions , by Region USD Million (2015-2020)
  • Table 11. Pharmacogenomics Academic Institutes , by Region USD Million (2015-2020)
  • Table 12. Pharmacogenomics Others , by Region USD Million (2015-2020)
  • Table 13. Pharmacogenomics: by Application Names(USD Million)
  • Table 14. Pharmacogenomics Cardiovascular Diseases , by Region USD Million (2015-2020)
  • Table 15. Pharmacogenomics Infectious Diseases , by Region USD Million (2015-2020)
  • Table 16. Pharmacogenomics Oncology , by Region USD Million (2015-2020)
  • Table 17. Pharmacogenomics Neurological Diseases , by Region USD Million (2015-2020)
  • Table 18. Pharmacogenomics Psychiatry , by Region USD Million (2015-2020)
  • Table 19. Pharmacogenomics Pain Management , by Region USD Million (2015-2020)
  • Table 20. Pharmacogenomics Others , by Region USD Million (2015-2020)
  • Table 21. South America Pharmacogenomics, by Country USD Million (2015-2020)
  • Table 22. South America Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 23. South America Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 24. South America Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 25. Brazil Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 26. Brazil Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 27. Brazil Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 28. Argentina Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 29. Argentina Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 30. Argentina Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 31. Rest of South America Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 32. Rest of South America Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 33. Rest of South America Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 34. Asia Pacific Pharmacogenomics, by Country USD Million (2015-2020)
  • Table 35. Asia Pacific Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 36. Asia Pacific Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 37. Asia Pacific Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 38. China Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 39. China Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 40. China Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 41. Japan Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 42. Japan Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 43. Japan Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 44. India Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 45. India Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 46. India Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 47. South Korea Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 48. South Korea Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 49. South Korea Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 50. Taiwan Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 51. Taiwan Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 52. Taiwan Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 53. Australia Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 54. Australia Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 55. Australia Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 56. Rest of Asia-Pacific Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 57. Rest of Asia-Pacific Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 58. Rest of Asia-Pacific Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 59. Europe Pharmacogenomics, by Country USD Million (2015-2020)
  • Table 60. Europe Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 61. Europe Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 62. Europe Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 63. Germany Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 64. Germany Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 65. Germany Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 66. France Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 67. France Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 68. France Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 69. Italy Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 70. Italy Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 71. Italy Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 72. United Kingdom Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 73. United Kingdom Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 74. United Kingdom Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 75. Netherlands Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 76. Netherlands Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 77. Netherlands Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 78. Rest of Europe Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 79. Rest of Europe Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 80. Rest of Europe Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 81. MEA Pharmacogenomics, by Country USD Million (2015-2020)
  • Table 82. MEA Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 83. MEA Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 84. MEA Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 85. Middle East Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 86. Middle East Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 87. Middle East Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 88. Africa Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 89. Africa Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 90. Africa Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 91. North America Pharmacogenomics, by Country USD Million (2015-2020)
  • Table 92. North America Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 93. North America Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 94. North America Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 95. United States Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 96. United States Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 97. United States Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 98. Canada Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 99. Canada Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 100. Canada Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 101. Mexico Pharmacogenomics, by Technology USD Million (2015-2020)
  • Table 102. Mexico Pharmacogenomics, by End User USD Million (2015-2020)
  • Table 103. Mexico Pharmacogenomics, by Application Names USD Million (2015-2020)
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Pharmacogenomics: by Technology(USD Million)
  • Table 115. Pharmacogenomics Sequencing , by Region USD Million (2021-2026)
  • Table 116. Pharmacogenomics Polymerase Chain Reaction , by Region USD Million (2021-2026)
  • Table 117. Pharmacogenomics Gel Electrophoresis , by Region USD Million (2021-2026)
  • Table 118. Pharmacogenomics Mass Spectrometry , by Region USD Million (2021-2026)
  • Table 119. Pharmacogenomics Microarray , by Region USD Million (2021-2026)
  • Table 120. Pharmacogenomics Others , by Region USD Million (2021-2026)
  • Table 121. Pharmacogenomics: by End User(USD Million)
  • Table 122. Pharmacogenomics Hospitals & Clinics , by Region USD Million (2021-2026)
  • Table 123. Pharmacogenomics Research Institutions , by Region USD Million (2021-2026)
  • Table 124. Pharmacogenomics Academic Institutes , by Region USD Million (2021-2026)
  • Table 125. Pharmacogenomics Others , by Region USD Million (2021-2026)
  • Table 126. Pharmacogenomics: by Application Names(USD Million)
  • Table 127. Pharmacogenomics Cardiovascular Diseases , by Region USD Million (2021-2026)
  • Table 128. Pharmacogenomics Infectious Diseases , by Region USD Million (2021-2026)
  • Table 129. Pharmacogenomics Oncology , by Region USD Million (2021-2026)
  • Table 130. Pharmacogenomics Neurological Diseases , by Region USD Million (2021-2026)
  • Table 131. Pharmacogenomics Psychiatry , by Region USD Million (2021-2026)
  • Table 132. Pharmacogenomics Pain Management , by Region USD Million (2021-2026)
  • Table 133. Pharmacogenomics Others , by Region USD Million (2021-2026)
  • Table 134. South America Pharmacogenomics, by Country USD Million (2021-2026)
  • Table 135. South America Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 136. South America Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 137. South America Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 138. Brazil Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 139. Brazil Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 140. Brazil Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 141. Argentina Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 142. Argentina Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 143. Argentina Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 144. Rest of South America Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 145. Rest of South America Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 146. Rest of South America Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 147. Asia Pacific Pharmacogenomics, by Country USD Million (2021-2026)
  • Table 148. Asia Pacific Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 149. Asia Pacific Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 150. Asia Pacific Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 151. China Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 152. China Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 153. China Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 154. Japan Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 155. Japan Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 156. Japan Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 157. India Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 158. India Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 159. India Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 160. South Korea Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 161. South Korea Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 162. South Korea Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 163. Taiwan Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 164. Taiwan Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 165. Taiwan Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 166. Australia Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 167. Australia Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 168. Australia Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 169. Rest of Asia-Pacific Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 170. Rest of Asia-Pacific Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 171. Rest of Asia-Pacific Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 172. Europe Pharmacogenomics, by Country USD Million (2021-2026)
  • Table 173. Europe Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 174. Europe Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 175. Europe Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 176. Germany Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 177. Germany Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 178. Germany Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 179. France Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 180. France Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 181. France Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 182. Italy Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 183. Italy Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 184. Italy Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 185. United Kingdom Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 186. United Kingdom Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 187. United Kingdom Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 188. Netherlands Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 189. Netherlands Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 190. Netherlands Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 191. Rest of Europe Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 192. Rest of Europe Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 193. Rest of Europe Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 194. MEA Pharmacogenomics, by Country USD Million (2021-2026)
  • Table 195. MEA Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 196. MEA Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 197. MEA Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 198. Middle East Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 199. Middle East Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 200. Middle East Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 201. Africa Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 202. Africa Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 203. Africa Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 204. North America Pharmacogenomics, by Country USD Million (2021-2026)
  • Table 205. North America Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 206. North America Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 207. North America Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 208. United States Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 209. United States Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 210. United States Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 211. Canada Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 212. Canada Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 213. Canada Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 214. Mexico Pharmacogenomics, by Technology USD Million (2021-2026)
  • Table 215. Mexico Pharmacogenomics, by End User USD Million (2021-2026)
  • Table 216. Mexico Pharmacogenomics, by Application Names USD Million (2021-2026)
  • Table 217. Research Programs/Design for This Report
  • Table 218. Key Data Information from Secondary Sources
  • Table 219. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pharmacogenomics: by Technology USD Million (2015-2020)
  • Figure 5. Global Pharmacogenomics: by End User USD Million (2015-2020)
  • Figure 6. Global Pharmacogenomics: by Application Names USD Million (2015-2020)
  • Figure 7. South America Pharmacogenomics Share (%), by Country
  • Figure 8. Asia Pacific Pharmacogenomics Share (%), by Country
  • Figure 9. Europe Pharmacogenomics Share (%), by Country
  • Figure 10. MEA Pharmacogenomics Share (%), by Country
  • Figure 11. North America Pharmacogenomics Share (%), by Country
  • Figure 12. Global Pharmacogenomics share by Players 2020 (%)
  • Figure 13. Global Pharmacogenomics share by Players (Top 3) 2020(%)
  • Figure 14. Global Pharmacogenomics share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Abbott Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Abbott Laboratories, Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Affymetrix, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Affymetrix, Inc. (United States) Revenue: by Geography 2020
  • Figure 20. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 22. Assurex Health (United States) Revenue, Net Income and Gross profit
  • Figure 23. Assurex Health (United States) Revenue: by Geography 2020
  • Figure 24. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 26. GeneDX (United States) Revenue, Net Income and Gross profit
  • Figure 27. GeneDX (United States) Revenue: by Geography 2020
  • Figure 28. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 30. Illumina, Inc., (United States) Revenue, Net Income and Gross profit
  • Figure 31. Illumina, Inc., (United States) Revenue: by Geography 2020
  • Figure 32. Myriad Genetics, Inc., (United States) Revenue, Net Income and Gross profit
  • Figure 33. Myriad Genetics, Inc., (United States) Revenue: by Geography 2020
  • Figure 34. Merck & Co, (United States) Revenue, Net Income and Gross profit
  • Figure 35. Merck & Co, (United States) Revenue: by Geography 2020
  • Figure 36. Global Pharmacogenomics: by Technology USD Million (2021-2026)
  • Figure 37. Global Pharmacogenomics: by End User USD Million (2021-2026)
  • Figure 38. Global Pharmacogenomics: by Application Names USD Million (2021-2026)
  • Figure 39. South America Pharmacogenomics Share (%), by Country
  • Figure 40. Asia Pacific Pharmacogenomics Share (%), by Country
  • Figure 41. Europe Pharmacogenomics Share (%), by Country
  • Figure 42. MEA Pharmacogenomics Share (%), by Country
  • Figure 43. North America Pharmacogenomics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories, Inc. (United States)
  • Affymetrix, Inc. (United States)
  • AstraZeneca plc (United Kingdom)
  • Assurex Health (United States)
  • Bayer AG (Germany)
  • GeneDX (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Illumina, Inc., (United States)
  • Myriad Genetics, Inc., (United States)
  • Merck & Co, (United States)
Additional players considered in the study are as follows:
GE Healthcare (United States) , GlaxoSmithKline, (United Kingdom) , Johnson & Johnson (United States) , Pfizer, Inc., (United States) , Pathway Genomics (United States) , Qiagen, Inc. (Germany) , Teva Pharmaceutical Industries Ltd (Israel) , Thermo Fisher Scientific (United States) , Transgenomic, Inc. (United States)
Select User Access Type

Key Highlights of Report


Nov 2021 212 Pages 65 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pharmacogenomics Market Quantitative research analysis
Global Pharmacogenomics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Pharmacogenomics market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Pharmacogenomics market are Abbott Laboratories, Inc. (United States), Affymetrix, Inc. (United States), AstraZeneca plc (United Kingdom), Assurex Health (United States), Bayer AG (Germany), GeneDX (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc., (United States), Myriad Genetics, Inc., (United States) and Merck & Co, (United States), to name a few.
In this highly competitive & fast evolving Pharmacogenomics industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Pharmacogenomics Market Report?

Have a Query? Click Here

Other Related Reports

Magnetic Beads Comprehensive Study by Application (Human Cell Separation, Animal cell separation (clinical study), Secondary cell separation), End Users (Healthcare Facilities (Hospitals, Clinics, an...
$ 3750
Bioanalytical Services Comprehensive Study by Type (Discovery bioanalysis services, Non-clinical bioanalysis services, Clinical bioanalysis services), Application (Pharmaceutical Industry, Biotechnol...
$ 3750
Rapid Influenza Diagnostic Test Comprehensive Study by Type (Digital RIDTs, Conventional RIDT), Application (Hospitals & Clinics, Laboratories, Other), Test (Point-of-Care test, Nucleic Acid Test, Im...
$ 3350
Animal Biotechnology Comprehensive Study by Type (Animal Genomics, Animal Cloning, Genetic Engineering of Animals), Application (Preventive Care for Animals, Development of Animal Pharmaceuticals, Fo...
$ 3450
Bioproducts Comprehensive Study by Type (Conventional Bioproducts, Emerging Bioproducts), Application (Building Materials, Pulp and Paper, Forest Products, Medical, Energy, Chemical Industry, Agricul...
$ 3650
Stable Isotopes Labelled Compounds Comprehensive Study by Type (Carbon-13, Nitrogen-15, Oxygen-18, Deuterium, Other Isotopes), Application (Research {Biomedical Research, Pharmaceutical Research, Env...
$ 3750